Arizona's Bioscience Roadmap

A Plan for Global Competitiveness

biotech

Welcome to Arizona’s Bioscience Roadmap, a long-term strategic plan originally commissioned by the Flinn Foundation in 2002 and updated in 2014 with the goal of Arizona becoming globally competitive and a national leader in select areas of the biosciences by 2025.

“Arizona’s Bioscience Roadmap 2014-2025: Advancing the Biosciences and Improving Health Outcomes” features five overarching goals, 17 strategies, and 77 potential actions. The goals focus on forming an entrepreneurial hub, turning research into practice, developing bio-talent, connecting research with health care delivery and commercialization, and enhancing the state’s “collaborative gene” reputation.

The updated Roadmap plan was compiled by the Battelle Technology Partnership Practice based on research and input from Arizona leaders in science, business, academia, and government, as well as national bioscience experts. Battelle also produced the comprehensive study released in 2002 that found Arizona possessed many of the essential elements needed to become a global leader in niche areas in the biosciences, but must strengthen its biomedical-research base and build a critical mass of bioscience firms and jobs.

Battelle has tracked performance data throughout the first decade, which was reported in these annual brochures. In future years, metrics will continue to be commissioned and reported publicly by the Flinn Foundation. The Roadmap has been and will continue to be guided by Arizona’s Bioscience Roadmap Steering Committee, which is comprised of about 100 state leaders in science, business, economic development, and government that meet quarterly.

Here is the vision for Arizona’s Bioscience Roadmap 2014-2025:

“Arizona is globally competitive and a national leader in the biosciences in such fields as precision medicine, cancer, neurosciences, bioengineering, diagnostics, and agricultural biotechnology. It excels in offering a deep talent base, a critical mass of entrepreneurs and enterprises, and clinical excellence to turn discovery into firms, products, and talent.”